After 12 hours of peptide presence, the liver samples from the murine models were collected and analyzed
Results from a 20-week phase 1b clinical trial showed that a once-weekly dose of 2.4 mg cagrilintide in combination with an equal dose of semaglutide, collectively termed cagrisema, achieved up to 17.1% weight reduction in the obese population
One notable example is the class of medications known as glucagon-like peptide-1 (GLP1) receptor agonists, which affect metabolism, inflammation, and cardiovascular health
Buse JB, Bergenstal RM, Glass LC, et al
While semaglutide provides pharmacological appetite suppression, patients achieve optimal outcomes by combining medication with evidence-based lifestyle modifications
Table of Contents: Is Zepbound a GLP-1 medication